Quantifying the prognostic significance of microRNA-17/17-5P in cancers: a meta-analysis based on published studies
Received 22 January 2018
Accepted for publication 29 March 2018
Published 17 July 2018 Volume 2018:10 Pages 2055—2069
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Fujiao Duan,1 Yang Yang,2 Weigang Liu,3 Jie Zhao,4 Xiaoqin Song,4 Lifeng Li,4 Fuqin Li2
1Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan, China; 2Department of Nosocomial Infection Management, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; 3Medical Record Statistics Office, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056002, China; 4Center of Telemedicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450008, China
Objective: The aim of this study was to investigate the prognostic value of mircoRNA-17 and mircoRNA-17-5P (miR-17/17-5P) in patients with cancer.
Materials and methods: We conducted a comprehensive search on published literature following the guidelines of the meta-analysis of observational studies in epidemiology group for design, implementation, and reporting. The methodological qualities for included studies were assessed using the quality in prognosis studies. The pooled hazard ratios (HRs) with 95% CIs for overall survival (OS) and progression-free survival/recurrence-free survival/disease-free survival (PFS/RFS/DFS) were calculated to appraise the associations between miR-17/17-5P expression and cancer prognosis.
Results: A total of 21 studies involving 2099 subjects were analyzed in evidence synthesis. The results showed that high expression of miR-17 was associated with poor OS (HR=2.14; 95% CI: 1.69–2.71, P<0.001) in patients with cancer, especially in Caucasian (HR=2.23; 95% CI: 1.58–3.14, P<0.001) and digestive tract cancer (HR=1.29, 95% CI: 1.03–1.63, P=0.03), and miR-17 expression was significantly correlated with PFS/RFS in cancer patients (HR=1.69, 95% CI: 1.29–2.22, P<0.001). miR-17-5P overexpression was significantly linked with poor OS in cancer patients (HR=1.66; 95% CI: 1.31–2.09, P=0.00), especially in Asian (HR=1.81; 95% CI: 1.37–2.40, P<0.001), digestive tract cancer (HR=1.80; 95% CI: 1.29–2.50, P<0.001), and serum sample (HR=1.76; 95% CI: 1.29–2.41, P<0.001). miR-17-5P expression was significantly associated with DFS in cancer patients (HR=1.58, 95% CI: 1.07–2.35, P=0.02).
Conclusion: High expression of miR-17 and miR-17-5P are significantly associated with poor survival in patients with cancer. This indicated that miR-17/17-5P may be a novel prognostic indicator in cancer.
Keywords: miR-17/17-5P, prognosis, cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]